Oncology - CurrentMed (Page 3)

Pharmacology

Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer – real-world data from a multicenter German patient population

PMCID: PMC12176970 PMID: 40533571 DOI: 10.1007/s00432-025-06239-1 Journal: Journal of cancer research and clinical oncology Publication Date: 2025-6-18 Authors: Gerhardt F, Müller C, Venerito M, Chater J, Mohr R, et al. Key Points * First real-world validation of ICI-based therapy for advanced biliary tract cancers using gemcitabine/cisplatin and durvalumab

Oncology

Oral Soft Tissue and Jawbone Sarcomas: A Retrospective Clinicopathologic Analysis of 128 Cases from Two Institutions and Comprehensive Literature Review

PMCID: PMC12174025 PMID: 40526340 DOI: 10.1007/s12105-025-01811-0 Journal: Head and neck pathology Publication Date: 2025-6-17 Authors: Argyris PP, Dennis GR, Gopalakrishnan R, Koutlas IG, McNamara KK, et al. Key Points * Osteosarcoma and Kaposi sarcoma collectively represent two-thirds of oral soft tissue and jawbone sarcomas * Male-to-female ratio of 1.5:

Pharmacology

Targeting circulating tumor cell‒neutrophil interactions: nanoengineered strategies for inhibiting cancer metastasis

PMCID: PMC12175327 PMID: 40528159 DOI: 10.1186/s12951-025-03522-8 Journal: Journal of nanobiotechnology Publication Date: 2025-6-17 Authors: Su Y, Leng M, Yang Q, Jiang W, Xiang G, et al. Key Points * Neutrophil-CTC interactions are a critical mechanism driving cancer metastasis through multiple biological processes * Nanotechnology-based drug delivery systems show promise in

Pharmacology

An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia

PMCID: PMC12174973 PMID: 40528704 DOI: 10.1158/2767-9764.CRC-25-0023 Journal: Cancer research communications Publication Date: 2025-6 Authors: Nagahashi M, Komatsu M, Urano S, Kuroiwa M, Takahashi Y, et al. Key Points * Pro-FTY selectively targets and inhibits breast cancer cells, including multidrug-resistant variants, using an acrolein-responsive drug delivery system * Demonstrated 100%

Immunology

Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy

PMCID: PMC12175482 PMID: 40530896 DOI: 10.1002/cam4.70994 Journal: Cancer medicine Publication Date: 2025-6-18 Authors: Wang F, Chen W, Jia Y, He T, Wu S, et al. Key Points * Intestinal microbiota significantly modulates immunotherapy response in colorectal cancer * Specific bacterial strains can enhance CD8+ T cell infiltration and cytotoxicity

Pharmacology

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation

PMCID: PMC12170901 PMID: 40523897 DOI: 10.1038/s41392-025-02274-z Journal: Signal transduction and targeted therapy Publication Date: 2025-6-17 Authors: Ruan DY, Wu HX, Xu Y, Munster PN, Deng Y, et al. Key Points * First study with the highest proportion of Asian mCRC patients receiving a KRAS G12C inhibitor, demonstrating promising anti-tumor

Immunology

Clinical factors associated with growth and neoantigen reactivity of tumor infiltrating lymphocytes from metastatic epithelial cancers

PMCID: PMC12179044 PMID: 40536705 DOI: 10.1007/s00262-025-04091-3 Journal: Cancer immunology, immunotherapy : CII Publication Date: 2025-6-19 Authors: Gustafson AM, Dinerman AJ, Hitscherich KJ, Parkhurst MR, Halas H, et al. Key Points * Lung metastases demonstrated superior TIL growth (95%) compared to other resection sites * 51% of TIL harvests showed high neoantigen

Oncology

A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery after neoadjuvant chemotherapy (LYMRIN-Trial): Project study by the Japan Pancreas Society and JON 2302-P

PMCID: PMC12173190 PMID: 40526592 DOI: 10.1371/journal.pone.0325667 Journal: PloS one Publication Date: 2025-6-17 Authors: Kimura N, Shirai Y, Itoh A, Hirano K, Shibuya K, et al. Key Points * Comprehensive multicenter study addressing optimal lymph node dissection in PDAC * Evaluating metastasis rates across different pancreatic tumor locations to

Pharmacology

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment

PMCID: PMC12175699 PMID: 40526090 DOI: 10.18632/oncotarget.28744 Journal: Oncotarget Publication Date: 2025 Authors: Hernando-Calvo A, Kurzrock R, Gonzalez NS, Magidi S, Bresson C, et al. Key Points * Comprehensive molecular profiling revealed multiple actionable genetic alterations in mCRC * Personalized treatment strategies proposed, including targeted therapies matching specific mutations * Repeated

Gastroenterology

Single-cell dissection of prognostic architecture and immunotherap response in Helicobacter pylori infection-associated gastric cancer

PMCID: PMC12173458 PMID: 40525824 DOI: 10.7554/eLife.99337 Journal: eLife Publication Date: 2025-6-17 Authors: Zhang X, Zhang G, Sang S, Fei Y, Cao X, et al. Key Points * H. pylori infection fundamentally reshapes gastric cancer's tumor microenvironment, increasing inflammatory and angiogenic cellular components * iCAF abundance and angiogenic

Oncology

Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression

PMCID: PMC12174346 PMID: 40527915 DOI: 10.1038/s41467-025-59888-8 Journal: Nature communications Publication Date: 2025-6-17 Authors: Yang H, Song H, Yip E, Gilpatrick T, Chang K, et al. Key Points * HV bladder cancers harbor a unique tumor cell state with distinct molecular characteristics, primarily expressing CA125, MUC4, and KRT24 * CA125+ cells

Oncology

The DCDC2/ENO1 axis promotes tumor progression and immune evasion in intrahepatic cholangiocarcinoma via activating FGL1-LAG3 checkpoint

PMCID: PMC12175362 PMID: 40533767 DOI: 10.1186/s13046-025-03436-1 Journal: Journal of experimental & clinical cancer research : CR Publication Date: 2025-6-18 Authors: Wan W, Li Y, Sun W, Cheng Z, Ma F, et al. Key Points * Anti-DCDC2 autoantibodies emerge as a potential novel diagnostic biomarker for intrahepatic cholangiocarcinoma * DCDC2 promotes ICC